Skip to main content
Circio Holding ASA logo

Circio Holding ASA — Investor Relations & Filings

Ticker · CRNA ISIN · NO0013033795 LEI · 5967007LIEEXZXFYNS31 OL Professional, scientific and technical activities
Open in API
Filings indexed 170 across all filing types
Latest filing 2026-05-26 Share Issue/Capital Cha…
Country NO Norway
Listing OL CRNA

About Circio Holding ASA

https://www.targovax.com/en/

Circio Holding ASA is a clinical-stage company developing novel medicines based on circular RNA (circRNA) and immunotherapy. The company's core focus is its proprietary circVec platform, a circular RNA expression system designed to enhance the efficacy and durability of gene and cell therapies. Circio's development pipeline is directed towards immuno-oncology, targeting difficult-to-treat solid tumors, and the application of its circRNA technology to address genetic diseases.

Recent filings

Filing Released Lang Actions
Announcement of the terms of the underwriting and the Unused Warrants Option Agreement in connection with the Warrant Program
Share Issue/Capital Change Classification · 85% confidence The document is a stock exchange announcement detailing the terms of a warrant program, including new share subscription rights, underwriting agreements, private placements deviating from shareholders’ preferential rights, and capital raising proceeds. It is an announcement of a new share issue/capital change rather than a financial report, management commentary, or regulatory filing report. Therefore, it falls under Share Issue/Capital Change (SHA).
2026-05-26 English
Commencement of exercise period for the Warrants
Share Issue/Capital Change Classification · 79% confidence The document is a corporate announcement detailing the opening of the exercise period for warrants, the exercise price, key dates, and subsequent share capital increase. It describes the mechanics for warrant exercise and issuance of new shares, which is a capital structure change event. This fits the definition of a Share Issue/Capital Change announcement rather than a detailed financing report or regulatory filing.
2026-05-26 English
Warrants exercise period commences today potential proceeds to transform Circio into a clinical-stage circular RNA company
Capital/Financing Update Classification · 85% confidence The document is a stock exchange announcement from Circio Holding ASA describing the commencement of a warrant exercise period, exercise price, underwriting, use of proceeds, and the resulting fundraising/capital structure change. It is clearly about a financing activity rather than a voting, management, or regulatory report. This matches the Capital/Financing Update category.
2026-05-26 English
Circio Holding ASA: Exercise price for Warrants set at NOK 8.2508
Capital/Financing Update Classification · 96% confidence The document is a press release announcing the exercise price for warrants issued in connection with a rights issue and private placement. It details terms, dates, and financing instructions under the warrant program. This is an update on the company’s capital structure and financing activities rather than a full report, regulatory certification, or proxy filing. Therefore, it fits the Capital/Financing Update category.
2026-05-22 English
Circio invites to a live webcast on 28 May 2026 to summarize the presentations at ASGCT 2026 and provide an overview of the warrants program
Capital/Financing Update Classification · 72% confidence The document is a stock exchange announcement inviting investors to a live webcast summarizing presentations at a scientific meeting and providing an overview of the company’s warrant program and planned use of proceeds. It is not a full financial report, regulatory certification, or voting notice, but rather an update on the company’s financing activity (warrant exercise period, subscription terms, use of proceeds). This fits the definition of a Capital/Financing Update (CAP).
2026-05-22 English
Circio files EPO patent application covering critical aspects of its circVec platform for enhanced gene and cell therapy
Regulatory Filings Classification · 72% confidence The document is a press release announcing that Circio has filed an EPO patent application (intellectual property event). It contains no financial statements, earnings, management changes, dividend notices, share transactions, or other specific corporate filings, and is not the publication of a report itself. None of the defined specialized categories match a patent filing announcement. Therefore, it falls into the fallback category Regulatory Filings (RNS).
2026-05-21 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.